

Table S3: LDL-cholesterol differences at 2.5 years with use of simvastatin plus ezetimibe in SHARP

	Differences between ezetimibe/simvastatin- and placebo-allocated participants		Estimated LDL-C difference (mmol/L) between ezetimibe/simvastatin- and placebo-allocated participants with full adherence to ezetimibe/simvastatin
	Net use of any LDL-C lowering treatment	LDL-C difference (mmol/L)	
5-year risk of cardiovascular disease			
<10%	66%	0.95	1.44
10% - 20%	61%	0.87	1.43
≥20%	58%	0.74	1.28
CKD stage at randomization			
3 ¹	66%	0.98	1.48
4	68%	1.05	1.54
5, not on dialysis	56%	0.72	1.29
On dialysis	54%	0.60	1.11
All patients	61%	0.85	1.39

LDL-C, LDL-cholesterol; CVD, cardiovascular disease; CKD, chronic kidney disease.

¹83% of participants in this category with CKD stage 3b (eGFR ≥30 to <45 ml/min/1.73m²)